Gastrointestinal Cancer Market By Cancer Type (Colorectal Cancer, Stomach Cancer, Esophageal Cancer, Pancreatic Cancer, Liver Cancer, Others), By Treatment (Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy, Surgery, Others), By Diagnostics (Endoscopy, Biopsy, Molecular Diagnostics, Imaging, Others), By End-User (Hospitals, Oncology Centers, Research Institutes, Diagnostic Laboratories), Global Market Size, Segmental Analysis, Regional Overview, Company Share Analysis, Leading Company Profiles And Market Forecast, 2025 – 2035.

Table of Contents

1. Methodology & Report Coverage

1.1. Definition & Objective

1.2. Market Evaluation & forecast parameter

1.3. Research Methodology

1.4. Data Validation Sources

1.4.1. Secondary Research

1.4.2. Primary Research

2. Market Overview

3. Gastrointestinal Cancer Market: Market Dynamics

3.1. Executive Summary

3.2. Market Driving Factors

3.2.1. Rising incidence of GI cancers due to lifestyle changes and aging populations.

3.2.2. Advancements in molecular diagnostics, enabling early detection and personalized treatment.

3.2.3. Increased investment in R&D for novel therapies like immunotherapy and targeted treatments.

3.3. Key industry pitfalls & challenges

3.3.1. High cost of treatments like immunotherapy limits accessibility for patients.

3.3.2. Severe side effects from chemotherapy and radiation impact patient adherence.

3.3.3. Late-stage diagnosis due to lack of early detection in developing regions.

3.4. Market Opportunities

3.4.1. Increasing demand for cancer treatments and diagnostics in emerging markets.

3.4.2. Development of liquid biopsy technologies for non-invasive early cancer detection.

3.4.3. AI adoption enhances diagnostic accuracy and treatment planning.

3.5. Porter’s Five Forces Analysis

3.6. PESTLE Analysis

3.7. Regulatory landscape

3.8. Investment Landscape

3.9. ESG Scenario

3.10. Competitive landscape

3.10.1. Company Market Share

3.10.2. Market Positioning

3.10.3. Strategy framework

3.10.4. Recent Acquisitions & Mergers

4. Gastrointestinal Cancer Market, Cancer Type Segment Analysis

4.1. Overview Dynamics

4.1.1. Market Revenue Share, By Cancer Type, 2025 & 2035

4.1.2. Key Market Trends, Growth Factors, & Opportunities

4.2. Colorectal Cancer

4.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.3. Stomach Cancer

4.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.4. Esophageal Cancer

4.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.5. Pancreatic Cancer

4.5.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.6. Liver Cancer

4.6.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.7. Others

4.7.1. Market Size and Forecast, 2025-2035 (USD Billion)

5. Gastrointestinal Cancer Market, Treatment Segment Analysis

5.1. Overview

5.1.1. Market Revenue Share, By Treatment, 2025 & 2035

5.1.2. Key Market Trends, Growth Factors, & Opportunities

5.2. Chemotherapy

5.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.3. Immunotherapy

5.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.4. Targeted Therapy

5.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.5. Radiation Therapy

5.5.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.6. Surgery

5.6.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.7. Others

5.7.1. Market Size and Forecast, 2025-2035 (USD Billion)

6. Gastrointestinal Cancer Market, Diagnostics Segment Analysis

6.1. Overview

6.1.1. Market Revenue Share, By Diagnostics, 2025 & 2035

6.1.2. Key Market Trends, Growth Factors, & Opportunities

6.2. Endoscopy

6.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.3. Biopsy

6.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.4. Molecular Diagnostics

6.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.5. Imaging

6.5.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.6. Others

6.6.1. Market Size and Forecast, 2025-2035 (USD Billion)

7. Gastrointestinal Cancer Market, End-user Segment Analysis

7.1. Overview

7.1.1. Market Revenue Share, By End-user, 2025 & 2035

7.1.2. Key Market Trends, Growth Factors, & Opportunities

7.2. Hospitals

7.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

7.3. Oncology Centers

7.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

7.4. Research Institutes

7.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

7.5. Diagnostic Laboratories

7.5.1. Market Size and Forecast, 2025-2035 (USD Billion)

7.6. Others

7.6.1. Market Size and Forecast, 2025-2035 (USD Billion)

8. Gastrointestinal Cancer Market, Region Segment Analysis

8.1. Overview

8.1.1. Global Market Revenue Share, By Region, 2025 & 2035

8.1.2. Global Market Revenue, By Region, 2025-2035(USD Billion)

8.2. North America

8.2.1. North America Market Revenue, By Country, 2025-2035(USD Billion)

8.2.2. North America Market Revenue, By Cancer Type, 2025-2035

8.2.3. North America Market Revenue, By Treatment, 2025-2035

8.2.4. North America Market Revenue, By Diagnostics, 2025-2035

8.2.5. North America Market Revenue, By End-user, 2025-2035

8.2.6. The U.S.

8.2.6.1. U.S. Market Revenue, By Cancer Type, 2025-2035

8.2.6.2. U.S. Market Revenue, By Treatment, 2025-2035

8.2.6.3. U.S. Market Revenue, By Diagnostics, 2025-2035

8.2.6.4. U.S. Market Revenue, By End-user, 2025-2035

8.2.7. Canada

8.2.7.1. Canada Market Revenue, By Cancer Type, 2025-2035

8.2.7.2. Canada Market Revenue, By Treatment, 2025-2035

8.2.7.3. Canada Market Revenue, By Diagnostics, 2025-2035

8.2.7.4. Canada Market Revenue, By End-user, 2025-2035

8.3. Europe

8.3.1. Europe Market Revenue, By Country, 2025-2035(USD Billion)

8.3.2. Europe Market Revenue, By Cancer Type, 2025-2035

8.3.3. Europe Market Revenue, By Treatment, 2025-2035

8.3.4. Europe Market Revenue, By Diagnostics, 2025-2035

8.3.5. Europe Market Revenue, By End-user, 2025-2035

8.3.6. Germany

8.3.6.1. Germany Market Revenue, By Cancer Type, 2025-2035

8.3.6.2. Germany Market Revenue, By Treatment, 2025-2035

8.3.6.3. Germany Market Revenue, By Diagnostics, 2025-2035

8.3.6.4. Germany Market Revenue, By End-user, 2025-2035

8.3.7. France

8.3.7.1. France Market Revenue, By Cancer Type, 2025-2035

8.3.7.2. France Market Revenue, By Treatment, 2025-2035

8.3.7.3. France Market Revenue, By Diagnostics, 2025-2035

8.3.7.4. France Market Revenue, By End-user, 2025-2035

8.3.8. U.K.

8.3.8.1. U.K. Market Revenue, By Cancer Type, 2025-2035

8.3.8.2. U.K. Market Revenue, By Treatment, 2025-2035

8.3.8.3. U.K. Market Revenue, By Diagnostics, 2025-2035

8.3.8.4. U.K. Market Revenue, By End-user, 2025-2035

8.3.9. Italy

8.3.9.1. Italy Market Revenue, By Cancer Type, 2025-2035

8.3.9.2. Italy Market Revenue, By Treatment, 2025-2035

8.3.9.3. Italy Market Revenue, By Diagnostics, 2025-2035

8.3.9.4. Italy Market Revenue, By End-user, 2025-2035

8.3.10. Spain

8.3.10.1. Spain Market Revenue, By Cancer Type, 2025-2035

8.3.10.2. Spain Market Revenue, By Treatment, 2025-2035

8.3.10.3. Spain Market Revenue, By Diagnostics, 2025-2035

8.3.10.4. Spain Market Revenue, By End-user, 2025-2035

8.3.11. Rest of Europe

8.3.11.1. Rest of Europe Market Revenue, By Cancer Type, 2025-2035

8.3.11.2. Rest of Europe Market Revenue, By Treatment, 2025-2035

8.3.11.3. Rest of Europe Market Revenue, By Diagnostics, 2025-2035

8.3.11.4. Rest of Europe Market Revenue, By End-user, 2025-2035

8.4. Asia Pacific

8.4.1. Asia Pacific Market Revenue, By Country, 2025-2035(USD Billion)

8.4.2. Asia Pacific Market Revenue, By Cancer Type, 2025-2035

8.4.3. Asia Pacific Market Revenue, By Treatment, 2025-2035

8.4.4. Asia Pacific Market Revenue, By Diagnostics, 2025-2035

8.4.5. Asia Pacific Market Revenue, By End-user, 2025-2035

8.4.6. China

8.4.6.1. China Market Revenue, By Cancer Type, 2025-2035

8.4.6.2. China Market Revenue, By Treatment, 2025-2035

8.4.6.3. China Market Revenue, By Diagnostics, 2025-2035

8.4.6.4. China Market Revenue, By End-user, 2025-2035

8.4.7. Japan

8.4.7.1. Japan Market Revenue, By Cancer Type, 2025-2035

8.4.7.2. Japan Market Revenue, By Treatment, 2025-2035

8.4.7.3. Japan Market Revenue, By Diagnostics, 2025-2035

8.4.7.4. Japan Market Revenue, By End-user, 2025-2035

8.4.8. India

8.4.8.1. India Market Revenue, By Cancer Type, 2025-2035

8.4.8.2. India Market Revenue, By Treatment, 2025-2035

8.4.8.3. India Market Revenue, By Diagnostics, 2025-2035

8.4.8.4. India Market Revenue, By End-user, 2025-2035

8.4.9. Australia

8.4.9.1. Australia Market Revenue, By Cancer Type, 2025-2035

8.4.9.2. Australia Market Revenue, By Treatment, 2025-2035

8.4.9.3. Australia Market Revenue, By Diagnostics, 2025-2035

8.4.9.4. Australia Market Revenue, By End-user, 2025-2035

8.4.10. South Korea

8.4.10.1. South Korea Market Revenue, By Cancer Type, 2025-2035

8.4.10.2. South Korea Market Revenue, By Treatment, 2025-2035

8.4.10.3. South Korea Market Revenue, By Diagnostics, 2025-2035

8.4.10.4. South Korea Market Revenue, By End-user, 2025-2035

8.4.11. Singapore

8.4.11.1. Singapore Market Revenue, By Cancer Type, 2025-2035

8.4.11.2. Singapore Market Revenue, By Treatment, 2025-2035

8.4.11.3. Singapore Market Revenue, By Diagnostics, 2025-2035

8.4.11.4. Singapore Market Revenue, By End-user, 2025-2035

8.4.12. Rest of Asia Pacific

8.4.12.1. Rest of Asia Pacific Market Revenue, By Cancer Type, 2025-2035

8.4.12.2. Rest of Asia Pacific Market Revenue, By Treatment, 2025-2035

8.4.12.3. Rest of Asia Pacific Market Revenue, By Diagnostics, 2025-2035

8.4.12.4. Rest of Asia Pacific Market Revenue, By End-user, 2025-2035

8.5. Latin America

8.5.1. Latin America Market Revenue, By Country, 2025-2035(USD Billion)

8.5.2. Latin America Market Revenue, By Cancer Type, 2025-2035

8.5.3. Latin America Market Revenue, By Treatment, 2025-2035

8.5.4. Latin America Market Revenue, By Diagnostics, 2025-2035

8.5.5. Latin America Market Revenue, By End-user, 2025-2035

8.5.6. Brazil

8.5.6.1. Brazil Market Revenue, By Cancer Type, 2025-2035

8.5.6.2. Brazil Market Revenue, By Treatment, 2025-2035

8.5.6.3. Brazil Market Revenue, By Diagnostics, 2025-2035

8.5.6.4. Brazil Market Revenue, By End-user, 2025-2035

8.5.7. Argentina

8.5.7.1. Argentina Market Revenue, By Cancer Type, 2025-2035

8.5.7.2. Argentina Market Revenue, By Treatment, 2025-2035

8.5.7.3. Argentina Market Revenue, By Diagnostics, 2025-2035

8.5.7.4. Argentina Market Revenue, By End-user, 2025-2035

8.5.8. Mexico

8.5.8.1. Mexico Market Revenue, By Cancer Type, 2025-2035

8.5.8.2. Mexico Market Revenue, By Treatment, 2025-2035

8.5.8.3. Mexico Market Revenue, By Diagnostics, 2025-2035

8.5.8.4. Mexico Market Revenue, By End-user, 2025-2035

8.5.9. Rest of Latin America

8.5.9.1. Rest of Latin America Market Revenue, By Cancer Type, 2025-2035

8.5.9.2. Rest of Latin America Market Revenue, By Treatment, 2025-2035

8.5.9.3. Rest of Latin America Market Revenue, By Diagnostics, 2025-2035

8.5.9.4. Rest of Latin America Market Revenue, By End-user, 2025-2035

8.6. MEA

8.6.1. MEA Market Revenue, By Country, 2025-2035(USD Billion)

8.6.2. MEA Market Revenue, By Cancer Type, 2025-2035

8.6.3. MEA Market Revenue, By Treatment, 2025-2035

8.6.4. MEA Market Revenue, By Diagnostics, 2025-2035

8.6.5. MEA Market Revenue, By End-user, 2025-2035

8.6.6. GCC Countries

8.6.6.1. GCC Countries Market Revenue, By Cancer Type, 2025-2035

8.6.6.2. GCC Countries Market Revenue, By Treatment, 2025-2035

8.6.6.3. GCC Countries Market Revenue, By Diagnostics, 2025-2035

8.6.6.4. GCC Countries Market Revenue, By End-user, 2025-2035

8.6.7. South Africa

8.6.7.1. South Africa Market Revenue, By Cancer Type, 2025-2035

8.6.7.2. South Africa Market Revenue, By Treatment, 2025-2035

8.6.7.3. South Africa Market Revenue, By Diagnostics, 2025-2035

8.6.7.4. South Africa Market Revenue, By End-user, 2025-2035

8.6.8. Rest of Middle-East & Africa

8.6.8.1. Rest of Middle-East & Africa Market Revenue, By Cancer Type, 2025-2035

8.6.8.2. Rest of Middle-East & Africa Market Revenue, By Treatment, 2025-2035

8.6.8.3. Rest of Middle-East & Africa Market Revenue, By Diagnostics, 2025-2035

8.6.8.4. Rest of Middle-East & Africa Market Revenue, By End-user, 2025-2035

9. Company Profile

9.1. Ferring Holding SA

9.1.1. Business Overview

9.1.2. Financial Performance

9.1.3. Product/Service Offerings

9.1.4. Strategies & recent developments

9.1.5. SWOT Analysis

9.2. Bristol-Myers Squibb Company

9.2.1. Business Overview

9.2.2. Financial Performance

9.2.3. Product/Service Offerings

9.2.4. Strategies & recent developments

9.2.5. SWOT Analysis

9.3. Eli Lilly and Company

9.3.1. Business Overview

9.3.2. Financial Performance

9.3.3. Product/Service Offerings

9.3.4. Strategies & recent developments

9.3.5. SWOT Analysis

9.4. Merck & Co., Inc.

9.4.1. Business Overview

9.4.2. Financial Performance

9.4.3. Product/Service Offerings

9.4.4. Strategies & recent developments

9.4.5. SWOT Analysis

9.5. Boehringer Ingelheim International GmbH

9.5.1. Business Overview

9.5.2. Financial Performance

9.5.3. Product/Service Offerings

9.5.4. Strategies & recent developments

9.5.5. SWOT Analysis

9.6. Roche Holding AG

9.6.1. Business Overview

9.6.2. Financial Performance

9.6.3. Product/Service Offerings

9.6.4. Strategies & recent developments

9.6.5. SWOT Analysis

9.7. AstraZeneca PLC

9.7.1. Business Overview

9.7.2. Financial Performance

9.7.3. Product/Service Offerings

9.7.4. Strategies & recent developments

9.7.5. SWOT Analysis

9.8. Amgen Inc.

9.8.1. Business Overview

9.8.2. Financial Performance

9.8.3. Product/Service Offerings

9.8.4. Strategies & recent developments

9.8.5. SWOT Analysis

9.9. Novartis AG

9.9.1. Business Overview

9.9.2. Financial Performance

9.9.3. Product/Service Offerings

9.9.4. Strategies & recent developments

9.9.5. SWOT Analysis

9.10. Sanofi S.A.

9.10.1. Business Overview

9.10.2. Financial Performance

9.10.3. Product/Service Offerings

9.10.4. Strategies & recent developments

9.10.5. SWOT Analysis

9.11. Pfizer Inc.

9.11.1. Business Overview

9.11.2. Financial Performance

9.11.3. Product/Service Offerings

9.11.4. Strategies & recent developments

9.11.5. SWOT Analysis

9.12. Johnson & Johnson

9.12.1. Business Overview

9.12.2. Financial Performance

9.12.3. Product/Service Offerings

9.12.4. Strategies & recent developments

9.12.5. SWOT Analysis

9.13. Celgene Corporation

9.13.1. Business Overview

9.13.2. Financial Performance

9.13.3. Product/Service Offerings

9.13.4. Strategies & recent developments

9.13.5. SWOT Analysis

9.14. Regeneron Pharmaceuticals, Inc.

9.14.1. Business Overview

9.14.2. Financial Performance

9.14.3. Product/Service Offerings

9.14.4. Strategies & recent developments

9.14.5. SWOT Analysis

9.15. Exelixis, Inc.

9.15.1. Business Overview

9.15.2. Financial Performance

9.15.3. Product/Service Offerings

9.15.4. Strategies & recent developments

9.15.5. SWOT Analysis